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Background: Although DNA vaccine holds a great potential for cancer immunotherapy, effective long-lasting
antitumoral immunity sufficient to induce durable responses in cancer patients remains to be achieved. Considering
the pivotal role of dendritic cells (DC) in the antigen processing and presentation, we prepared DC-targeting DNA
vaccines by fusing tumor-associated antigen HER2/neu ectodomain to single chain antibody fragment (scFv) from
NLDC-145 antibody specific for DC-restricted surface molecule DEC-205 (scFvNLDC-145), and explored its antitumoral
efficacy and underlying mechanisms in mouse breast cancer models.
Results: In vivo targeting assay demonstrated that scFvNLDC-145 specifically delivered DNA vaccine-encoded antigen
to DC. Compared with untargeted HER2/neu DNA vaccines, vaccination with scFvNLDC-145-HER2/neu markedly
promoted the HER2/neu-specific cellular and humoral immune responses with long-lasting immune memory,
resulting in effective protection against challenge of HER2/neu-positive D2F2/E2 breast tumor while ineffective in
parental HER2/neu-negative D2F2 breast tumor. More importantly, in combination with temporary depletion of
regulatory T cells (Treg) by low-dose cyclophosphamide, vaccination with scFvNLDC-145-HER2/neu induced the
regression of established D2F2/E2 breast tumor and significantly retarded the development of spontaneous
mammary carcinomas in transgenic BALB-neuT mice.
Conclusion: Our findings demonstrate that DC-targeted DNA vaccines for in vivo direct delivery of tumor antigens
to DC could induce potent antigen-specific cellular and humoral immune responses and, if additional combination
with systemic Treg depletion, was able to elicit an impressively therapeutic antitumoral activity, providing a
rationale for further development of this approach for cancer treatment.
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During the last 20 years, DNA-based immunization has
been rapidly developed as a new approach to prime spe-
cific cellular and humoral immune responses to protein
antigens [1]. In mouse models, DNA vaccines have been
successfully directed against many types of tumor with
tumor protection reproducibly observed in an antigen-
specific manner [2]. However, conventional DNA vaccines* Correspondence: foxp3_smmu@163.com; yanjianvv@gmail.com
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reproduction in any medium, provided the orwith only the encoded antigen failed to mount an effective
T-cell immunity in human trials, even when delivered by
in vivo electroporation, which calls for a novel design for
DNA vaccine [1,2].
It is critical for DNA vaccination to be successful that
encoded proteins are taken up, processed, and presented
by dendritic cells (DC), the most potent antigen-
presenting cells (APC) in vivo that initiate the adaptive
immunity. Following intradermal or intramuscular injec-
tion of a plasmid DNA vaccine in mice, the encoded
gene is expressed in transfected keratinocytes and
myocytes at the site of injection [3] as well as a small
number of DC [4-6]. Keratinocytes and myocytes are
poorly effective in presenting antigen and priming naive
immune cells due to lack of expression of MHC class II. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cess to T cells in lymphoid tissues, as is the case for DC
[7]. It is thought that transduced DC initiate immune
priming process, which can be further boosted by anti-
gen released from other long-lived transfected cells [8,9].
Therefore, targeting DNA vaccines to DC should im-
prove the efficacy of DNA vaccines. In fact, a recent
study demonstrated that DC-targeted DNA vaccines
elicited much higher level of antibody and antigen-
specific T cells, leading to effective protection against
virus expressing encoded antigen [10].
Coupling of antigens to ligands or antibodies that spe-
cifically bind to DC receptors has been widely used as a
means of DC targeting [11]. Using this approach, a
lowered requirement for antigen dose in stimulating im-
mune responses in mice has been observed after
targeting a variety of molecules, including MHC class II,
DEC205, CD11c, Dectin-1/2, mannose receptor, and
CD36 [12-17]. The studies have also shown that anti-
bodies specific for the mannose receptor or DC-SIGN
could effectively deliver antigen to human DCs, indicat-
ing that this strategy may also be applicable to human
vaccination [18,19].
Overexpression of the HER-2 receptor tyrosine kinase
has been found in various human malignancies, includ-
ing breast, ovarian and gastric carcinomas, non-small
cell lung cancer, and salivary gland cancers, and has
been associated with poor prognosis of patients [20,21].
Endogenous HER2-specific CD4+ T cells and antibodies
have been detected in patients with HER2-expressing can-
cers [22,23], and in clinical trials, HER2-specific CD4+ and
CD8+ T-cell responses could be induced by peptide vac-
cination [24,25]. These studies provide strong supports for
HER2 being an important tumor antigen for targeted
immunotherapy. The clinically approved HER2-targeted
immunotherapy involves infusion of humanized HER2-
specific monoclonal antibody Herceptin; ref. [26]. Al-
though Herceptin has been shown to be effective in
inhibiting tumor growth in a limited population of HER2-
postive metastatic breast cancer patients, elicitation of an
active and more comprehensive immune response that in-
cludes both antibody and T-cell responses may provide
more effective protection [27].
Here, we prepared DC-targeting DNA vaccines by
fusing tumor-associated antigen HER2/neu ectodo-
main (HER2/neu, residues 22 to 561 or 22 to 582) to
single chain antibody fragment (scFv) from NLDC-145
(scFvNLDC-145), a monoclonal antibody binding the
mouse DC-restricted surface molecule DEC-205, and
evaluated the preventive and therapeutic effects
of these DNA vaccines in HER2/neu-positive mouse
breast tumor models. We further characterized
the cellular mechanisms driving antitumor effect of
DC-targeted DNA vaccines elucidating the basicprocesses necessary to achieve immune-mediated
tumor rejection.Methods
Mice and cell lines
Six to 8-week-old female BALB/c (H-2d) mice were pur-
chased from the Animal Experimental Center of the Sec-
ond Military Medical University. BALB-neuT mice (H-2d)
expressing a transforming neu under the control of mouse
mammary tumor virus promoter were obtained from
Charles River Laboratories (Shanghai, China). Heterozy-
gous 6- to 15-week-old virgin females expressing rat
neu as verified by PCR were used throughout this work.
All animal studies were approved by the Institutional
Review Board of the Second Military Medical Univer-
sity, Shanghai, China.
Mouse thymoma cell line EL4, breast cancer cell line
4 T1, and 293 T cell line were purchased from ATCC
(American Type Culture Collection, VA, USA). The cells
were maintained in DMEM supplemented with 10%
FCS, 4 mmol/L glutamine, 100 units/mL penicillin and
100 μg/mL streptomycin. D2F2/E2 and EL4/E2 stably
expressing human wild-type HER2 were maintained in
complete DMEM medium containing 0.4 mg/mL G418
(Sigma-Aldrich). TUBO cells are neu-expressing breast
carcinoma cells established from a lobular carcinoma of
a female BALB-neuT mouse [28], and maintained in
DMEM containing 20% FCS. Murine lymphocytes were
cultured in RPMI-1640 containing 10% FCS, 2 mmol/L
glutamine and 50 μmol/L 2-mercaptoethanol. All tissue
culture reagents were purchased from Life Technologies
unless described otherwise.Reagents
Peptides used in this study were obtained from Sigma-
Aldrich. All peptides were > 95% pure as indicated by
analytical HPLC. Lyophilized peptides were diluted in
DMSO and stored at - 20°C until use. Recombinant
HER2 and TRP2 protein were purchased from R&D Sys-
tems. Cyclophosphamide (CTX) were obtained from
Sigma-Aldrich and reconstituted in sterile PBS (20 mg/
mL) for in vivo injections. Monoclonal antibodies
(mAbs) to the following antigens were purchased from
eBiosciences (San Diego, CA): CD4 (GK 1.5) and CD8
(53–6.7) conjugated to fluorescein isothiocyanate (FITC);
CD11c (N418) and Foxp3 (FJK-16 s) conjugated to
phycoerythrin (PE); mAbs to PE-TNF-α (MP6-XT22)
and PE-IFN-γ (XMG1.2) were purchased from BD
PharMingen (San Jose, CA). Immunoglobulins with
isotypes corresponding to the above mAbs and conju-
gated to the appropriate fluorochromes, were used as
control for nonspecific binding.
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The backbone for the construction of DNA vaccines was
the mammalian expression vector pcDNA3.1 (Invitrogen).
In this vector encoding vaccine proteins are expressed
under the control of the CMV promoter as an in-frame
fusion with an antibody kappa chain signal peptide (SP)
sequence (amino acid MDFQVQIFSFLLISASVIISRG) for
secretion and are followed by C-terminal His tag for de-
tection. The genes encoding the variable regions of the
heavy (VH) and light (VL) chains of scFvNLDC-145 were
synthesized according to the published sequences [29].
Each VH fragment was bound to its VL partner by use of
a spacer encoding a 15 amino-acid flexible linker
(Gly4Sert)3, yielding scFv constructs scFv
NLDC-145. The se-
quence encoding for the extracellular domain of human
HER2 or its rat homologue neu was amplified from cDNA
of SK-BR-3 and TUBO cell lines using the following
primers HER2-HindIII-s 5′-TTAAGCTTAG CACCCAA
GTGTGCACCGGCAC-3′, HER2-XbaI-as 5′-TTTCTAG
ACAAACAGTGCCTGGCATT CACATAC-3′ and neu-
HindIII-s 5′-TTAAGCTTGGAGCCGCGGGTACCCAA
GTGTG-3′, neu-XbaI -as 5′-TTTCTAGATCCAAAGCA
GGTCTCTGAGCTGTTTTGAG-3′.The resultant encod-
ing sequences were then cloned in-frame downstream of
the scFvNLDC-145. For in vivo targeting assay, we generated
pcDNA3.1-scFvNLDC-145-EGFP by replacing the HER2
fragment with EGFP sequence cloned from pEGFP-N1
plasmid. The pcDNA3.1 vector encoding EGFP without
DC-targeting scFv fragments as controls (pcDNA3.1 and
pcDNA3.1-EGFP).
Expression of protein encoded by DNA vaccines
The different pcDNA3.1 constructs were transiently
transfected in 293T cells using Lipofectamine 2000
according to the manual instruction (Invitrogen). The
resultant supernatants were harvested at 72 hours post-
transfection and concentrated and dialyzed using cen-
trifugal filter devices (Amicon Ultra, 10K, millipore).
Protein expression was analyzed by Western blotting
using recombinant anti-His mAb (ab1187, Abcam).
In vivo targeting assay
The 50 μg pcDNA3.1-scFvNLDC-145-EGFP and pcDNA3.1-
EGFP plasmids in 50 μL PBS were injected into the upper
leg muscle of the left hind limb of the mice followed by
in vivo electroporation as described previously [30]. One
day later, the lysate of the muscle tissues of injection site
were prepared using RIPA buffer and subjected to the
western blotting for detection of EGFP and scFvNLDC-145-
EGFP fusion protein by anti-EGFP antibody (ab111258,
Abcam) as described above. The spleens were harvested
from the injected mice at different time points (48, 60,
72 hours) and single-cell suspensions were prepared and
stained with PE-conjugated anti-CD11c antibody orisotype control for 30 min. The GFP fluorescence in the
CD11c-positive DC was analyzed by flow cytometry as de-
scribed previously [14].
Protective and therapeutic vaccination
For prophylactic vaccination, female BALB/c mice or
BALB-neuT mice were vaccinated on days −21 and −7
by intramuscular injections of 50 μg pcDNA3.1-
scFvNLDC-145-HER2/neu, pcDNA3.1-HER2/neu plasmid
DNA in 50 μL PBS as described above. As control,
50 μL pcDNA3.1 or 50 μL PBS were injected. On day 0,
animals were inoculated subcutaneously (s.c.) with 2 ×
105 D2F2/E2, D2F2 or TUBO tumor cells in the oppos-
ite flank. Tumor growth was monitored with a caliper by
measuring two perpendicular tumor diameters every
week, and tumor volumes were calculated according to
the formula: length × (width)2 × 0.5. For therapeutic
vaccination, when the tumors were 3–4 mm in diameter
(day 7), mice were injected intraperitoneally (i.p.) with
cyclophosphamide (100 mg/kg) in 100 μL PBS. Four
days later (day 11), animals were vaccinated as described
above. Vaccination was repeated once 14 days later, and
tumor growth was followed. If animals appeared mori-
bund or the diameter of the tumors reached 15 mm, the
mice were sacrificed and this was recorded as the date
of death for survival studies. For rechallenging experi-
ments, the long-term surviving mice were injected s.c.
either with 2 ×105 D2F2/E2, D2F2, or 4T1 tumor cells.
Prevention of spontaneous tumors
Preventive effects of the DNA vaccines were investi-
gated in virgin female BALB-neuT mice that endogen-
ously express neu in their mammary glands and
develop neu-driven mammary carcinomas [28]. Ani-
mals were immunized twice at 8 and 10 week ages as
described above. Mammary glands were inspected every
week to monitor the appearance of tumors. Measurable/
palpable masses >2 mm in diameter were regarded as tu-
mors. Data are reported as tumor multiplicity (cumulative
number of tumors per number of mice in each group) and
shown as mean ±SE.
Cytometric identification of regulatory T cells
For detection of regulatory T cells (Treg), splenocytes
from immunized mice were surface stained with FITC
anti-mouse CD4 (GK1.5; eBioscience). After that, cells
were washed with wash buffer (PBS with 1% fetal bovine
serum and 0.09% sodium azide), fixed and permeabilized
with the Cytofix/Cytoperm reagent (BD Bioscience) for
20 minutes at 4°C, after which they were washed in
Perm/Wash buffer (BD Bioscience), and stained with PE
anti-mouse Foxp3 (FJK-16 s; eBioscience) at 4°C for
30 minutes. Immunoglobulin G-PE and immunoglobulin
G-FITC (mouse) were used as negative controls. All
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Dickinson) flow cytometer.
Evaluation of T-cell responses
For detection of HER2-specific cellular immune re-
sponse, splenocytes from vaccinated mice were cultured
in 96-well flat-bottomed plates in 100 μL of growth
medium in the presence of 10 μg/mL recombinant
HER2 or TRP2 protein in vitro. After 80 h, [3H] thymi-
dine (1 μCi/well; Amersham) was added for the re-
maining 16 h of the assay. [3H] thymidine incorporation
was analyzed by liquid scintillation counting as described
previously [14]. The supernatants were also collected
and assayed for production of IFN-γ, TNF-α, IL-4, IL-10
by ELISA kits (R&D Systems).
For detection of IFN-γ and TNF-α-producing CD4 or
CD8 T cells, intracellular cytokine staining assays were
performed. Briefly, splenocytes harvested from vaccinated
mice were cultured in the presence of 10 μg/mL recom-
binant HER2 or TRP2 protein for 24 h. During the final
4 h of incubation, 10 μg/mL brefeldin A were added. After
surface staining with FITC-CD4 and FITC-CD8, cells were
permeabilized and stained with PE-IFN-γ and PE-TNF-α
prior to analysis by flow cytometry as described above. For
CTL measurements, 51Cr-release assays were performed
as described previously [14].
Analysis of antibody responses
Peripheral blood was collected from the tail vein of the
mice, and 1:100 dilutions of sera were analyzed by
ELISA with recombinant HER2 protein or by flow cy-
tometry using D2F2/E2 and TUBO tumor cells as de-
scribed previously [14]. Normal mouse serum served as
negative control.
Statistical analysis
Differences among tumor growth kinetics, tumor multipli-
city, and specific cytotoxicity were evaluated by ANOVA
or the Student’s test. Values of P < 0.05 were considered
significant. For survival studies, Kaplan-Meier survival
curves were plotted and analyzed using Prism 5.00 soft-
ware (GraphPad Software).
Results
Construction and expression of DNA vaccines
We obtained the genes encoding scFvNLDC-145 by whole
gene synthesis according to the published sequences
[29]. The carboxyl terminus of the scFvNLDC-145 was dir-
ectly fused in-frame to the sequences encoding the
extracellular domain of HER2 (amino acids 22–561) or
neu (amino acids 22–582) amplified from SK-BR-3 or
TUBO breast cell lines, followed by His tag (Figure 1A).
To confirm the expression of these constructs, 293T
cells were transiently transfected with these plasmids,and then supernatants were harvested 72 hours later
and tested for protein secretion by Western blotting. As
shown in Figure 1B, we detected the production of
scFvNLDC-145-HER2 and scFvNLDC-145-neu proteins (lane
1, 2) or HER2 and neu fragments (lane 3, 4) in the su-
pernatants by anti-His tag antibody respectively, and
their molecular weights were slightly larger than pre-
dicted, indicating certain extent of glycosylation.
scFvNLDC-145 targets antigen to DC in vivo
To test whether scFvNLDC-145 moiety delivery encoded
antigens into DC in vivo, we constructed pcDNA3.1-
scFvNLDC-145-EGFP and pcDNA3.1-EGFP plasmids
(Additional file 1: Figure S1), which facilitated us to
trace the final fate of antigens carried by scFvNLDC-145.
The animals were injected i.m. with scFvNLDC-145-EGFP
plasmids, sacrificed at different time points post-
injection, and splenocytes were harvested and probed
for GFP fluorescence by flow cytometry. We first
confirmed the comparative expression of EGFP and
scFvNLDC-145-EGFP fusion protein with correct molecu-
lar weight in the muscle tissue of injection site by west-
ern blotting (Figure 1C, right). As shown in Figure 1D,
approximate 50% CD11c-positive DC in the spleen
from pcDNA3.1-scFvNLDC-145-EGFP-treated animals
showed GFP fluorescence at 48 h post-injection, and
this percentage further went up, approaching about
65% at 60 h post-injection. Antigen loading was DC-
specific since CD11c-negative non-DC cells showed
few, if any, GFP fluorescence. A representative dot plot
obtained at 60 h post-injection was shown in Figure 1C,
left. In contrast, after injection of pcDNA3.1-EGFP
plasmid, some fluorescence slightly above background
levels were detectable, resulting in only 10% of DC be-
ing loaded (background level was 5%). The much lower
percentage of GFP-positive DC in pcDNA3.1-EGFP-
treated mice was not due to lower GFP expression
efficiency of pcDNA3.1-EGFP plasmid since total GFP-
positive cells in splenocytes were almost same from
mice receiving injection of these two constructs.
Protection of mice from challenge with HER2-expressing
tumor cells
To investigate whether immunization with DC-targeted
vaccines induce antitumoral immunity and protect ani-
mals from subsequent tumor challenge, BALB/c mice
were i.m. vaccinated twice at two week interval with
various vaccines. Seven days after last immunization, the
mice were subcutaneously challenged with HER2-
positive D2F2/E2 tumor cells, and tumor development
was monitored. As shown in Figure 2A, scFvNLDC-145-
HER2 vaccination protected mice from D2F2/E2 tumor
challenge, resulting in 100% survival in all mice during
the observation period (120 days after vaccination).
Figure 1 scFvNLDC-145 targets tumor antigen into DCs in vivo. A schematic representation of expression vectors. scFvNLDC-145-HER2, scFvNLDC-145-
neu, pcDNA3.1-HER2, or pcDNA3.1-neu encode under the control of a CMV promoter, all the fusion proteins consisting of an signal peptide, amino
acid residues 22 to 561 of human HER2 or amino acid residues 22 to 582 of rat neu, and COOH-terminal His tag. The control plasmids pcDNA3.1-HER2
and pcDNA3.1-neu lack the NLDC-145 domains. B 293T cells grown in 100-mm dishes were transfected with various expression vectors using
Lipofectamine 2000 (invitrogen). Immunoblot analysis of supernatants from 293T cells transfected with scFvNLDC-145-HER2, scFvNLDC-145-neu, pcDNA3.1-
HER2 and pcDNA3.1-neu (lane 1, 2, 3 and 4). Vaccine proteins were probed with mouse anti-His tag mAb followed by HRP-conjugated secondary anti-
mouse antibody. C left, scFvNLDC-145-EGFP plasmid and controls as indicated were injected i.m. into mice, spleens were removed 48, 60, and
72 h thereafter, and stained with PE-conjugated anti-CD11c antibody. The GFP fluorescence in splenocytes was measured by flow cytometry.
Representative results from one animal of each group 60 h post-injection. right, the expression of EGFP (MW,~25 kDa) and scFvNLDC-145-EGFP
(MW,~55 kDa) fusion protein in injected muscle tissues detected by western blotting using anti- EGFP antibody 24 h after plasmid injection
with GAPDH (MW,42 kDa) as loading control. Lane 1, mice treated with pcDNA3.1 control vaccine; lane 2, mice treated with EGFP-encoding
vaccine; lane 3, mice treated with scFvNLDC-145-EGFP vaccine; D percentages of GFP+ DC in total DC (left panel); Percentages of GFP+ in CD11c-
negative splenocytes (right panel). Bars, SE. *, P < 0.01, scFvNLDC-145-EGFP compared with other groups.
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exhibited slower tumor growth compared with those
treated with untargeted HER2 or neu DNA vaccine or
control pcDNA3.1, resulting in prolonged survival of
these mice, which indicated the induction of cross-
reactivity toward HER2 antigen by scFvNLDC-145-neu vac-
cination. To examine whether HER2-specific responses
induced by scFvNLDC-145-HER2 vaccines were respon-
sible for protection, a similar experiment was done using
parental HER2-negative D2F2 tumor cells. Rapid tumor
growth was observed in all animals regardless of eithertreatment (Figure 2B), suggesting that antitumor activity
against HER2-expressing D2F2/E2 tumor cells was due
to HER2-specific immune responses induced by
scFvNLDC-145-HER2. We also obtained a similar protect-
ive effect of scFvNLDC-145-HER2 in C57BL/6 mice using
paired EL/4 and EL4/E2 tumor models (data not
shown).
To test whether immunologic memory was developed,
long-term surviving mice initially vaccinated with
scFvNLDC-145-HER2 were rechallenged with D2F2/E2
tumor cells. The parental D2F2 cells or unrelated
Figure 2 Vaccination with scFvNLDC-145-HER2 protects mice from challenge with HER2-expressing tumor cells and induces memory
immune responses. A animals (10 mice per group) were vaccinated with HER2, neu, scFvNLDC-145-HER2 or scFvNLDC-145-neu on days −21 and −7.
Control animals received pcDNA3.1. On day 0, mice were inoculated s.c. with D2F2/E2 tumor cells. Tumor developments were monitored, and
animal survival was calculated. Left panel, kinetics of tumor growth; Right panel, survival curve. B the vaccinated animals were challenged with
parental HER2-negative D2F2 cells on day 0. C the long-term surviving mice from scFvNLDC-145-HER2 group were rechallenged with D2F2/E2,
D2F2, or syngeneic unrelated 4 T1 tumor cells 3 months after initial tumor challenge. Tumor growth was followed. Bars, SE. *, P < 0.001,
scFvNLDC-145-HER2 compared with other groups.
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Figure 2C, the mice rejected subsequent rechallenges
with the D2F2/E2 tumor cells and remained tumor-free,
however, the mice could not reject unrelated syngeneic
4 T1 tumor. Interestingly, mice were also resistant to the
rechallenge with the parental D2F2 tumor cells with 70%
of mice tumor-free and remaining mice displaying drastic-
ally slow tumor growth. In summary, these results indicate
that scFvNLDC-145-HER2 vaccination induced long-lasting
HER2-specific antitumor immunity, which could protect
mice from HER2-expressing tumor challenge.Induction of HER2-specific T cells
To analyze the nature of the immune responses induced
by scFvNLDC-145-HER2, splenocytes were isolated from the
vaccinated mice and cultured in the presence of recom-
binant HER2 or TRP2 protein for 3 days in vitro. As
shown in Figure 3A, left, splenocytes obtained from
scFvNLDC-145-HER2-vaccinated mice showed vigorous
proliferation upon stimulation with recombinant HER2
protein, but not TRP2 protein. A slightly increased prolif-
eration was also detected in the splenocytes fromscFvNLDC-145-neu-vaccinated mice. In contrast, no evident
T-cell proliferation could be observed when mice were
vaccinated with untargeted HER2 or neu.
The supernatants of stimulated T cells were tested for
the presence of cytokines by ELISA. Splenocytes obtained
from scFvNLDC-145-HER2-vaccinated mice produced sub-
stantial amounts of TNF-α and IFN-γ (Figure 3A, right);
similarly, a mildly higher level of IFN-γ and TNF-α
cytokine was also detected in the supernatant from
scFvNLDC-145-neu-vaccinated mice. We did not detect
the secretion of IL-4 and IL-10 cytokines with immuno-
suppressive activity in all groups.
Next, we evaluated for the induction of HER2-specific
CD4+ and CD8+ T cells. As shown in Figure 3C, a much
higher percentage of CD4+ and CD8+ T cells producing
IFN-γ and TNF-α was detected upon in vitro restimulation
with recombinant HER2 protein in splenocytes from
scFvNLDC-145-HER2-vaccinated mice. These T cells were
HER2-specific since no cells produced these two cytokines
upon restimulation with recombinant TRP2 pretein. A rep-
resentative dot plot was shown in Figure 3B. In addition,
splenocytes from scFvNLDC-145-HER2-vaccinated mice
exhibited significantly higher target cell killing than did
Figure 3 (See legend on next page.)
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Figure 3 Vaccination with scFvNLDC-145-HER2 induced HER2-specific cellular immune response. BALB/c mice were vaccinated with HER2,
scFvNLDC-145-neu or scFvNLDC-145-HER2. Control animals received PBS or pcDNA3.1. Spleens and peripheral blood were harvested from the
vaccinated animals after two vaccinations. A splenocytes isolated from the vaccinated animals were cultured in the presence of 10 μg/mL
recombinant HER2 or TRP2 protein for 4 d with the addition of [3H] thymidine in the last 16 h. T-cell proliferation was determined by [3H]
thymidine incorporation (left panel). Right panel, the supernatant recovered from the assay in left was tested for cytokine production by ELISA.
B intracellular staining for IFN-γ and TNF-α in splenocytes from the vaccinated animals stimulated with 10 μg/mL recombinant HER2 or TRP2
protein for 24 h and brefeldin A added during the final 4 h of incubation. One representative dot plots from scFvNLDC-145-HER2-vaccinated animal.
C percentage of CD4+TNF-α+, CD4+IFN-γ+, CD8+ TNF-α+ and CD8+ IFN-γ+ cells in total CD4+ and CD 8+ T cells from each group are shown. The
data are mean percentages ± SE. D splenocytes were cocultured with D2F2/E2 cells for 5 d. The resultant splenocytes (E) were cocultured for 4 h
with the 51Cr-labeled target cells (T) (left panel). Right panel, the restimulated splenocytes from scFvNLDC-145-HER2 vaccinated mice were also
cocultured for 4 h with the 51Cr-labeled D2F2 or EL4/E2 (different gene background control) target cells. Percentages of target cells killing by the
splenocytes from the vaccinated mice are shown. Data represent the means of triplicate cultures and are representative of two independent
experiments. Bars, SE. *, P < 0.01, **, P < 0.001, scFvNLDC-145-HER2 compared with other groups.
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city of the killing was validated by the inability of the
splenocytes to kill parental D2F2 target cells and EL4/E2
target cells with a different H-2b background (Figure 3D,
right). The cytotoxic effect was mediated by CD8+ T cells,
because the killing was inhibited by addition of anti-CD8,
but not anti-CD4, antibody (data not shown).
Induction of HER2-specific antibody
We also evaluated the induction of HER2-specific anti-
body. As shown in Figure 4A, vaccination with
scFvNLDC-145-HER2 induced a significantly highly level
of HER2-specific antibodies specifically binding to recom-
binant HER2 protein in ELISA assays. Detailed analysis of
antibody isotype demonstrated that antibodies induced by
scFvNLDC-145-HER2 vaccine was mainly IgG2a, which was
consistent with cytokine profile of splenocytes from
scFvNLDC-145-HER2-vaccinated mice (Figure 4A).
We also tested whether the sera of vaccinated mice
contained antibodies binding to “natural” D2F2/E2 cells.
As shown in Figure 4B, we detected D2F2/E2-specific anti-
bodies in sera derived from mice vaccinated with
scFvNLDC-145-HER2, whereas no antibodies were found in
other groups. In summary, the results show that scFvNLDC-
145-HER2-vaccinated mice developed antibodies that
recognize epitopes expressed by D2F2/E2 cells and thus
may also confer protection against tumor growth in vivo.
Therapeutic efficacy of scFvNLDC-145-HER2 vaccine
We next evaluated the therapeutic effect of scFvNLDC-
145-HER2 vaccination on established tumors in D2F2/E2
breast tumor model. BALB/c mice were subcutaneously
inoculated with D2F2/E2 tumor cells. On day 7, animals
with tumors sizing ~ 40 mm3 were randomized into
groups treated with scFvNLDC-145-HER2 or respective
controls. Treatment was repeated once 2 week later. As
shown in Figure 5A, scFvNLDC-145-HER2 vaccination
substantially slowed tumor development and protected
up to 20% (2/10) of the mice from tumor growth at the
end of experiment (120 days after tumor inoculation).Since regulatory T cells (Treg) have been shown to me-
diate immune-tolerance towards tumor-antigens in vari-
ous tumor models, we further tested whether systemic
depletion of regulatory T cells would increase the thera-
peutic efficacy of DC-targeting vaccine. An approach with
intraperitoneal injection of low-dose (100 mg/kg) cyclo-
phosphamide (CTX) that was successfully applied in vari-
ous models was utilized this study. As shown in Figure 5B,
low-dose CTX injection in the D2F2/E2-bearing mice effi-
ciently depleted Treg almost to the level in tumor-free
mice 4 days post-injection, however, no direct killing effect
on tumor cells were observed (data not shown). We there-
fore tested DC-targeted vaccines in combination with
Treg depletion by low-dose CTX. As shown in Figure 5C,
this combination significantly improved the therapeutic
effects of scFvNLDC-145-HER2 vaccine; at the end of experi-
ment, 80% (16/20) mice rejected the established tumor
and remaining 4 (20%) mice had stably small tumors
(~30 mm3). These tumor-free mice also rejected the
rechallenges with the same tumor cells (date not shown).
Untargeted DC vaccines failed to exert therapeutic effects
although this vaccine in combination with CTX mildly de-
layed tumor growth. The experiment was repeated with
similar results (date not shown). The data indicate that
DC-targeting vaccines are able to mount an impressively
therapeutic antitumor effect when in combination with
systemic Treg depletion.
Antitumoral activity of the scFvNLDC-145-neu DNA vaccine
in immunotolerant BALB-neuT mice
Tumor models based on human HER2-expressing
D2F2/E2 cells are useful to assess the basic functionality
of cancer vaccines, however, such models do not fully
reflect the situation of human cancer usually character-
ized by immunologic tolerance toward HER2. Therefore,
we further tested DC-targeted DNA vaccines in female
BALB-neuT mice that represent an immunotolerant
model of spontaneous cancer [28]. In these experiments,
we used scFvNLDC-145-neu instead of scFvNLDC-145-HER2
since the spontaneous tumors developed in BALB-neuT
Figure 4 Vaccination with scFvNLDC-145-HER2 induced HER2-
specific antibodies. BALB/c mice were vaccinated with HER2,
scFvNLDC-145-neu or scFvNLDC-145-HER2. Control animals received PBS
or pcDNA3.1. Sera were collected from the vaccinated animals after
two vaccinations. A HER2-specific total IgG and IgG subclass
(IgG1and IgG2a) antibodies in sera from the vaccinated animals after
1:100 dilution were determined by ELISA. The mean OD405 values
of pooled sera from each group (5 mice per group) were presented.
Bars, SE. The background OD405 of normal mouse sera was < 0.04.
B D2F2/E2 cells were incubated with the immune sera obtained
from the vaccinated animals, and surface bound antibodies were
detected using FITC-labeled secondary antibodies. Samples were
then analyzed by flow cytometry. The data were represented as
mean fluorescence intensity. Normal mouse sera served as control.
All results were representative of two independent experiments.
*, P < 0.01, scFvNLDC-145-HER2 compared with other groups.
Cao et al. BMC Immunology 2013, 14:39 Page 9 of 14
http://www.biomedcentral.com/1471-2172/14/39mice are driven by constitutively activated rat neu
protein.
We first evaluated the preventive efficacy of scFvNLDC-145-
neu vaccine using transplantable neu-expressing TUBOtumor model in BALB-neuT mice. BALB-neuT mice re-
ceived twice scFvNLDC-145-neu or control vaccination at
14 days interval. One week after last vaccination, the ani-
mals were challenged with TUBO tumor cells. As shown in
Figure 6A, the animals receiving scFvNLDC-145-neu vaccin-
ation were significantly protected against a subsequent chal-
lenge with TUBO cells. Sixty days after tumor challenge,
90% (9/10) mice in this group remained tumor free and 1
mouse had small tumors (~35 mm3). The experiment was
repeated with similar results (data not shown). Mechanistic
investigation showed that scFvNLDC-145-neu induced high
levels of neu-specific CTLs and antibodies (Figure 6B,C).
The effect of scFvNLDC-145-neu vaccination in the pre-
vention of spontaneous mammary tumors that naturally
arise in BALB-neuT mice was also evaluated. The
scFvNLDC-145-neu was given to the mice at week 8 from
birth when diffuse atypical hyperplasia is already evident
in the mammary glands but before in situ carcinoma is
evident [31] and repeated at week 10. Mice in one group
also received CTX injection 4 days before the first vac-
cination. As shown in Figure 6D, scFvNLDC-145-neu/CTX
vaccination resulted in a significant prolongation of
tumor-free survival. This corresponded with a marked
delay (~4 weeks) in the appearance of macroscopically
detectable tumors in the mammary glands of these mice.
By week 38, all of the mice that were vaccinated with
scFvNLDC-145-neu/CTX remained alive. In contrast, by
week 26, all of the mice in the control groups had large
tumors and required euthanasia. We again observed a
mildly protective effect in scFvNLDC-145-neu vaccination
group, in which the survival of most mice delayed to
week 30.Discussion
Although clinical trials have shown that DNA vaccines
could elicit immune responses in humans, the protective
potency is modest [2]. The reasons for the failure of
DNA vaccines to induce potent immune responses in
humans have not been elucidated. It is reasonable to as-
sume that low levels of antigen production, inefficient
antigen presentation and insufficient stimulation of APC
have roles in low potency of DNA vaccine [32].
Our results showed that scFvNLDC-145 could mediate
antigen to be effectively phagocytosed by the DC com-
pared with untargeted antigen in vivo. DEC205 expres-
sion is restricted to a subset of DC in mice that are
specialized to cross-present exogenous antigens with re-
sultant induction of MHC-I-restricted CD8+ CTLs and
also promote the development of MHC-II-restricted
CD4+ helper T cells [13,33]. Therefore, DEC205-carried
antigens can be targeted to DEC205+ cross-presenting
DC in the T-cell zone of spleen, which allows for antigen
presentation by DC to both CD4+ and CD8+ T cells and
Figure 5 Therapeutic efficacy of scFvNLDC-145-HER2 vaccine. A BALB/c mice (10 mice per group) were inoculated s.c. with D2F2/E2 tumor
cells. On day 7, animals with tumors sizing ~ 40 mm3 were immunized with scFvNLDC-145-HER2 or respective controls. Treatment was repeated on
day 21. Tumor developments were monitored, and animal survival was calculated. Left panel, kinetics of tumor growth; Right panel, survival curve.
The data were represented as the mean tumor volume (mm3) and representative of two experiments with comparable results. **, P < 0.01,
scFvNLDC-145-HER2 compared with other groups. B temporary depletion of CD4+ Foxp3+ regulatory T cells by a single injection of low-dose CTX.
BALB/c mice (3 mice per group) were inoculated s.c. with D2F2/E2 tumor cells. When the tumors were 3-4 mm in diameter (day 7), mice were
injected i.p. with CTX (CTX injected) or PBS (Tumor bearing). Naive mice (Untreated) were used as control. The spleens were harvested at different
time points and analyzed for the regulatory T cells. Left panel, Percentage of CD4+ Foxp3+ in total CD4+ cells; Right panel, a representative dot
plot. Bars, SE. *, P < 0.05, CTX group compared with other groups. C BALB/c mice (10 mice per group) were inoculated s.c. with D2F2/E2 tumor
cells. When the tumors were 3-4 mm in diameter (day 7), mice received CTX injection. Four days later (day 11), animals were vaccinated with
various DNA vaccines. Treatment was repeated after two weeks. Left panel, kinetics of tumor growth; Right panel, survival curve. The data were
represented as the mean tumor volume (mm3) and representative of two experiments with comparable results. **, P < 0.01, scFvNLDC-145-HER2/
CTX compared with other groups.
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Figure 6 Protective effects of scFvNLDC-145-neu in transgenic BALB-neuT mice. A female BALB-neuT mice (10 mice per group) were
vaccinated with neu or scFvNLDC-145-neu in left hind limb on days −21 and −7. Control animals received pcDNA3.1 or PBS. On day 0, mice were
inoculated s.c. with neu-expressing TUBO cells in opposite flank. Left panel, kinetics of tumor growth; Right panel, survival curve. *, P < 0.01,
scFvNLDC-145-neu compared with other groups. B in a separate experiment, splenocytes obtained from the vaccinated mice described above were
tested for tumor killing activity. Data represented the means of triplicate cultures. *, P < 0.01, scFvNLDC-145-neu compared with other groups.
C sera from the vaccinated mice described above were assayed for neu-specific antibodies by flow cytometry. The data were represented as
mean fluorescence intensity. *, P < 0.01, scFvNLDC-145-neu compared with other groups. D animals were immunized neu or scFvNLDC-145-neu twice
at weeks 8 and 10. One group mice with scFvNLDC-145-neu vaccination also received CTX injection 4 days before the first vaccination. Control
animals received pcDNA3.1 or PBS. Development of mammary tumors was monitored by manual examination of the mammary glands once
every week. Measurable masses of > 2 mm diameter were regarded as tumors. Points, mean number of tumors in each group (tumor multiplicity;
left panel) and percentage of tumor-free mice (right panel); bars, SE. All results were representative of two to three independent experiments.
*, P < 0.01, scFvNLDC-145-neu /CTX compared with other groups.
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immune response compared with conventional vaccines.
Confirming the pivotal role of CD8+ T cells, HER2-
specific CD8+ CTLs specifically lysing HER2-expressing
tumor cells were required to protect mice from HER2-
positive tumor growth since antibody-mediated deple-
tion of these cells abrogated the protective effects
conferred by scFvNLDC-145-HER2 vaccine (Additional file
2: Figure S2), which is also consistent with the previous
studies [34,35]. The scFvNLDC-145-HER2 vaccination in-
duced high titer of HER2-specific IgG2a antibodies, indi-
cating Th1-biased immune response. The data are also
concordant with two recent studies showing vaccination
with DNA vaccines encoding antigen fused to scFvNLDC-145
generated significantly stronger T-cell and antibody-specific
responses compared with that elicited by untargeted vac-
cines [10,29].
The immune responses induced by scFvNLDC-145-
HER2 vaccination were directed specifically against
HER2 antigen as evidenced by protecting against HER2-
positive D2F2/E2 but not parental HER2-negative D2F2
tumor cells in vaccinated animals. In addition, scFvNLDC-
145-HER2 vaccination induced immunologic memory
with vaccinated mice resistant to subsequent rechallenge
with D2F2/E2 and D2F2 cells. Presumably, the develop-
ment of long-term immunologic memory was not only
dependent on the HER2 antigen but also on other un-
identified antigens of D2F2/E2 tumor. Because antigen-
negative variants may arise after antigen-positive tumor
cells are destroyed, immune responses to additional un-
defined tumor-associated antigens may be crucial to the
ultimate success of vaccination [14,31].
Vaccination with scFvNLDC-145-HER2 provided up to
20% of mice from HER2-positive tumor development in
the therapeutic setting. The weakly therapeutic potency
was possibly due to the insufficiency of local immune re-
sponses mounted by targeted DNA vaccine alone since
pretreatment of mice with cyclophosphamide signifi-
cantly increased the protective effects conferred by
targeted vaccine with tumor regressed in 80% of mice.
Low-dose CTX is known to selectively deplete Tregcells, with the nadir at day 4, and recovery to pretreat-
ment levels by day 10 [36]. In addition, CTX has other
immunomodulatory effects, including Th2/Th1 switch
[37]; induction of type I IFN [38]; and the activation of
DC [39]. It has also been reported that CTX pretreat-
ment can remodel the local immune profile with in-
creased IFN-γ-producing CD4+ and CD8+ effector T
cells and decreased Treg cells in tumor microenviron-
ment [40]. Consistent with previous studies [36,40], we
observed that CTX treatment significantly decreased
both peripheral (Figure 5B) and tumor-infiltrated Treg
cells (data not shown), which may consequently promote
local vaccine-induced CD8+ T-cell immune responses
and induce more potent protection. It needs further in-
vestigation to clarify the correlation between local im-
mune response and protective effects induced by
targeted vaccine. Considering that reagents are readily
available for depletion of Treg cells, our combined strat-
egy holds potential for clinical translation.
Vaccination with scFvNLDC-145-neu significantly protected
against a subsequent challenge with TUBO cells and
combination with Tregs ablation markedly delayed the
onset of spontaneous mammary carcinomas in BALB-
neuT mice. The data were consistent with previous studies
showing that Treg depletion enabled neu-specific CTL re-
sponses after vaccination of neu-transgenic FVB/N mice
with a cellular vaccine expressing neu and granulocyte
macrophage colony-stimulating factor [41] and was able
to break tolerance to the immunodominant TYVPANASL
epitope [42] and combined with peptide vaccination and
adjuvants markedly extended disease-free survival in
BALB-neuT mice [43]. Unlike protein-based DC-targeting
vaccines, which require the co-injection of additional DC
maturation stimuli to induce T cell responses [11,13,14],
DC targeting in a DNA format induces immunity without
additional adjuvant [28], possibly because the DNA itself
provides some signals for DC maturation [44]. It warrants
further study to determine whether the efficacy of DC-
targeting vaccines could be further improved by additional
stimuli that increase DC numbers and maturation state
and/or improve the function of the responding T cells.
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In summary, our results show that DC-targeting DNA
vaccines induce potent immune responses and provoke
superior antitumoral effects in mouse breast tumor
models; impressively, when combined with Treg deple-
tion, DC-targeting DNA vaccines induce the regression
of established tumor in transplantable tumors and sig-
nificantly retard spontaneous tumor development in
immunotolerant BALB-neuT mice. DEC205 is expressed
at high levels on a large fraction of DCs in the T cell
areas of lymphoid organs, including human lymphoid
tissues [45], and this give perspective for its application
in human. Since DC-targeting protein vaccines are being
evaluated in clinical trials [46], it would be feasible to
evaluate DC-targeting DNA vaccination in combination
with Treg depletion for cancer treatment.Additional files
Additional file 1: Figure S1. Construction and expression of pcDNA3.1-
scFvNLDC-145-EGFP and pcDNA3.1-EGFP a generated pcDNA3.1-scFvNLDC-
145-EGFP by replacing the HER2 fragment with EGFP sequence cloned
from pEGFP-N1 plasmid. The pcDNA3.1 vector encoding EGFP without
DC-targeting scFv fragment as control. b 293T cells grown in 24-well
plate were transfected with the two expression vectors using
Lipofectamine 2000 (invitrogen). Green fluorescent protein GFP was
observed by inverted fluorescence microscope (X51-A21PH, OLYMPUS).
Additional file 2: Figure S2. Analysis of cell population responsible for
the protective effects by targeted vaccine. Animals (5 mice per group)
were vaccinated with scFvNLDC-145-HER2 on days −21 and −7. On day 0,
mice were inoculated s.c. with D2F2/E2 tumor cells. For in vivo depletion
of CD4+, CD8+ T cells or CD19+ B cells, an anti-CD4 (0.5 mg/mouse;
Clone GK1.5), anti-CD8 (0.5 mg/mouse; Clone YTS 169.4), anti-CD19
(0.2 mg/mouse; Clone 1D3) or control (0.5 mg/mouse; Clone 2A3) mAb
was injected i.p. on days −7, -3 and −1 and repeated weekly later. All
mAbs were purchased from BioXcell. Tumor developments were
monitored, and animal survival was calculated.Competing interests
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